Background/Aims: Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporters, such as ABCB1, ABCC1, and ABCG2, is a key obstacle for successful cancer chemotherapy. There is currently no FDA-approved MDR modulator that can be used in clinic. Ceritinib, a selective ALK inhibitor, has been approved as the second-line treatment for ALKpositive non-small cell lung cancer. Here, we examined the role of ceritinib in leukemia associated MDR in therapy. Methods: The cell proliferation was detected by MTT assay. The flow cytometry was used to detect the expression of cell surface protein and to detect the accumulation and efflux of rhodamine 123 (Rh123) or doxorubicin (Dox) in cells. The RT-PCR and Western blot were performed to detect the gene expression and protein expression levels, respectively. Results: We found that ceritinib enhanced the efficacy of substrate chemotherapeutic agent in ABCB1-overexpressing K562/adr leukemia cells both in vitro and in vivo models, but neither in sensitive parental K562 leukemia cells nor in ABCC1-overexpressing HL-60/adr leukemia cells. Mechanistically, ceritinib significantly increased the intracellular accumulation of Rh123 or Dox but did neither alter ABCB1 expressions at both protein and mRNA levels nor block the phosphorylations of AKT and ERK1/2 at the concentration of MDR reversal. Importantly, ceritinib also increased the intracellular accumulation of Dox and enhanced the efficacy of Dox in primary leukemia cells in ex-vivo. Conclusion: Our results suggested that ceritinib enhanced the efficacy of substrate chemotherapeutic agent on inhibition of leukemia cell growth in vitro, in vivo and ex-vivo, which linked to block ABCB1 function, pumping out its substrate conventional chemotherapeutic agent, thereby increasing the intracellular accumulation. These suggest the combination of ceritinib and substrate chemotherapeutic drugs maybe an effective treatment of resistant leukemia patients with ABCB1-mediated MDR.
Introduction
In the hematological neoplasm, leukemia originates from abnormal hematopoietic stem cells which can result in a high number of abnormal white blood cells. Allogeneic hematopoietic stem cell transplantation (HSCT) is a radical therapy for leukemia, while it is only suitable for a minority of leukemia patients because of the lack of enough bone marrow donors. Therefore, most leukemia patients must be treated with conventional or targeted chemotherapy. Conventional chemotherapy, using cytotoxic drugs to inhibit the proliferation of malignant cells or destroy malignant cells, has become the most common and primary clinical strategy in the treatment of blood malignancies. The targeted chemotherapeutic drugs, such as the first FDA-approved tyrosine kinase inhibitor (TKI) imatinib has been used for treating chronic myeloid leukemia (CML) patients with oncoprotein BCR-ABL expression, which has resulted in well-pleasing and remarkable treatment outcomes for the majority of CML patients [1] [2] [3] . Unfortunately, multidrug resistance (MDR) is still the main reason for the failure and relapse of leukemia chemotherapy using conventional or targeted chemotherapeutic drugs.
MDR is a multi-mechanism phenomenon. The overexpression of ABC transporter proteins such as ABCB1, ABCC1 and ABCG2 has been proved to play a vital role in the development of MDR in cancer cells [4, 5] . The human genome contains 49 ABC genes, which are divided into A to G seven subfamilies. The ABC proteins encoded by these genes decrease intracellular drug accumulation by transporting cytotoxic anti-cancer drug outside of cancer cells. Hence, overexpression of ABC transporter can increase drug efflux and decrease the intracellular drug concentration, thereby preventing the tumor cells from being inhibited or killed. These survived tumor cells finally acquire drug resistance [6] . Among the ABCprotein family, proteins encoded by the ABCB1 (MDR1), ABCC1 (MRP1), and ABCG2 (MXR and BCRP) genes are the best known to associate with MDR [7] . Particularly, ABCB1 protein is the most frequently observed and widely studied molecular cause of MDR in ABC-protein family [8] [9] [10] . Normally, ABCB1 is often distributed in the kidney, pancreas, liver and gut, as a protection mechanism in the human body. Its overexpression has been reported to be related to poor response to chemotherapy and poor overall survival in leukemia patients [11, 12] . Based on this situation, various kinds of drugs including lapatinib [13] , cediranib [14] , alectinib [15] , and gefitinib [16] have been reported to reverse MDR by inhibiting the function of ABCB1. Although MDR modulators have been extensively studied, no MDR modulator has ever been approved by FDA for clinic application.
On the other hand, targeted chemotherapeutic drugs, such as tyrosine kinase inhibitors (TKIs), have been administrated to fight against cancer for decades. TKI is generally used as a monotherapy in clinic. However, drug combinations acting synergistically to kill cancer cells have increasingly become an important approach in cancer chemotherapy to prevent or delay the drug resistance. TKIs such as gefitinib [16] , erlotinib [17] , lapatinib [18] , apatinib [19] , crizotinib [20] , nilotinib [21] can enhance the efficacy of substrate anticancer agent in MDR cells. Ceritinib (LDK378, Novartis Pharmaceuticals) is an ATP-competitive, potent and selective second-generation ALK inhibitor which was approved by FDA on April 29, 2014 to treat non-small cell lung cancer [22, 23] . Since ceritinib mechanistically acts like other TKIs, it is conceivable that ceritinib may also sensitize the ABC transporter overexpressing leukemia cells to substrate chemotherapeutic drug, thereby reversing MDR.
Materials and Methods
Chemicals and reagents Ceritinib (LDK378) was purchased from Selleck Chemical (Houston, TX, USA). The molecular structure of ceritinib is shown in Fig. 1A . Monoclonal antibody against ABCB1, extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), p-ERK, AKT and p-AKT were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibody against glyceraldehyde-3-Phosphate dehydrogenase (GAPDH) was purchased from Kangcheng (Shanghai, China). RPMI-1640 and fetal bovine serum (FBS) were obtained from Gibco BRL (Thermo Fisher Scientific Inc., Waltham, MA, USA). Lymphocyte separation medium was from Zhanchen Inc. (Shanghai, China). Doxorubicin (Dox), paclitaxel, cisplatin, verapamil (VRP), dimethyl sulfoxide (DMSO), rhodamine123, and 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyl tetrazolium bromide (MTT), were all purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell lines and patient samples
It has been reported that the ABCB1 is expressed in AML/CML patients [24] . We obtained the bone marrow samples from AML/CML patients according to the FAB classification after getting their informed consent, and this study was approved by the Ethics Review Committee at Sun Yat-Sen University Cancer Center. The mononuclear cells were separated by lymphocyte separation medium and cultured in RPMI 1640 medium supplemented with 10% FBS at 37℃ in a humidified atmosphere of 5% CO2. K562, K562/ adr (K562/adr cells stably overexpress ABCB1 because of the long-term exposure of the parental K562 cell line to the ABCB1 substrate Dox), HL60, and Dox-selected ABCC1 overexpressing derivative cell line HL60/ adr were also cultured in the same medium mentioned above.
Cell cytotoxicity assay
The MTT assay was used to assess cytotoxicity as described previously [25] . Briefly, the cells (about 4000-8000 cells) growing in logarithmic phase were incubated overnight in 96-well microplates to the desired confluency before they were treated with the indicated concentration of each conventional chemotherapeutic drugs together with or without a fixed concentration of ceritinib or verapamil. When the cells were incubated in a humidified atmosphere containing 5% CO 2 at 37℃ for 68 h, MTT (5 mg/ml, 20 μL) was added into each well, and 4 h later, the medium was discarded gently after centrifugation and 100 μL DMSO was added into each well to dissolve the formazan product from the metabolism of MTT. Finally, optical density was measured at 540 nm, with background subtraction at 670 nm by a Model 550 Microplate Reader (Bio-Rad, Hercules, CA, USA). The half maximal (50%) inhibitory concentration (IC 50 ) value of a substrate was calculated by the Bliss method and the IC 50 results were presented as mean ± standard deviation (SD) [26] . The fold reversal of MDR was calculated as previously described [27] . All experiments were repeated at least three times.
In vivo experiment
We purchased athymic nude mice (5-6 weeks old) from the Vital River (Beijing, China). About 1×10 7 K562/adr cells were harvested and implanted subcutaneously under the shoulder in a nude mouse to establish the K562/adr cells xenograft model [27] . When the tumors reached a mean diameter of 0.5 cm, the mice were randomized into four groups and treated as follows: (1) The accumulation of Dox and rhodamine 123 (Rho 123) in leukemia cells Flow cytometry assay was performed to measure the effect of ceritinib on the intracellular accumulation of Dox and Rho123 in leukemia cells as previously described [28] . Briefly, the cells were cultured in the 6-well microplates and grown overnight. Then the cells were treated with saline or one of the different concentrations of ceritinib (0.5 μM, 0.25 μM, 0.125 μM) or 10 μM verapamil (VRP) (VRP was used as a positive control inhibitor in ABCB1-overexpressing cells.) at 37℃ for 3 h. Following the saline or ceritinib or VRP treatment, then 10 μM Dox was added to each well and cells were further incubated for 3 h or 5 μM Rho 123 was added to each well and cells were further incubated for 0.5 h, respectively. The cells were then harvested, washed 3 times with ice-cold PBS, and analyzed by CytomicsFC500 flow cytometer (Beckman Coulter, USA). All experiments were repeated at least three times.
Dox efflux examined in leukemia cells
Dox efflux was performed following a modification of the methods described earlier [29] . In brief, K562 and K562/adr cells were treated with 10 μM Dox for 3 h at 37℃, then the cells were washed three times with ice-cold PBS buffer and subsequently maintained at 37℃ with RPMI 1640 medium supplemented with 10% FBS without Dox in the presence or absence of 0.5 μM ceritinib for 0, 15, 30, 60, 90 and 120 min, until cells were collected and washed three times with ice-cold PBS buffer. Finally, cells were resuspended in icecold PBS buffer for immediate flow cytometric analysis (Beckman Coulter; CytomicsFC500). All experiments were repeated at least three times.
Western blot analysis
The Western blot was performed as previously described [30] . The protein expression of ABCB1 or the phosphorylation of AKT and ERK1/2 were evaluated in the ABCB1-overexpressing k562/adr cells and in their parental k562 cells after treatment with ceritinib (0.125, 0.25, and 0.5 μM) for 48 h. After treatment under the above conditions, cells were harvested and washed twice with ice-cold PBS buffer. Next, total cell lysates were generated in cell lysis buffer (1×PBS, 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 100 mg/mL phenylmethylsulfonyl fluoride, 10 mg/mL leupeptin, 10 mg/mL aprotinin). An equal amount of total protein from each cell lysate was resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and then transferred to PVDF membrane (Pall, USA). After blocking with 5% nonfat milk for one hour, PVDF membranes were sequentially incubated with the primary antibodies overnight at 4℃ and secondary antibodies for two hours at room temperature. After washing three times for 30 minutes with TBST buffer, the signal was developed using the enhanced chemiluminescence kit (#1705061, Bio-Rad, CA, USA) and detected by a Kodak medical X-ray processor (Kodak, Rochester, NY, USA).
PCR and real-time quantitative PCR
ABCB1 mRNA expression levels were assayed as previously described [30] . The PCR primers were 5′-CCCATCATTGCAATAGCAGG-3′ (forward) and 5′-GTTCAAACTTCTGCTCCTGA-3′ (reverse) for ABCB1, and 5′-CTTTGGTATCGTGGAAGGA-3′ (forward) and 5′-CACCCTGTTGCTGTAGCC-3′ (reverse) for GAPDH. After 35 cycles of amplification, products were separated by 1.0% agarose gel electrophoresis. Real-time quantitative PCR was performed using SYBR GREEN Mix (Molecular Research Center, Cincinnati, OH, USA). Relative quantification of ABCB1 was analyzed using the 2 -ΔΔCt method after normalization with GAPDH expression in each sample.
Detection of cell surface expression of ABCB1 by flow cytometer K562/adr and the leukemic blasts (We transferred each bone marrow or blood sample to a green topped tube containing heparin, then the mononuclear cells were isolated by Ficoll-Hypaque density centrifugation.) were collected and washed three times with an isotonic ice-cold PBS buffer supplemented with 0.5% bovine serum albumin (BSA). For ABCB1 expression analysis, approximately 1×10 6 cells (100 μL) were incubated at 4 ℃ for 45 min in the dark with 10 μL of PE-conjugated anti-human P-gp (Beckman Coulter, Fullerton, CA, USA), then the cells were washed twice with PBS buffer supplemented with 0.5% BSA and resuspended in 400 μL PBS buffer for flow cytometric analysis. Isotype control samples were treated with PE-conjugated mouse IgG2a antibody. All experiments were repeated at least three times.
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Statistical analysis
The data were expressed as mean ± SD. All experiments were repeated at least three times, and the statistical analyses were determined by Student's t-test. Statistical significance was considered when *P <0.05 or **P <0.01.
Results

Ceritinib potentiated the cytotoxicity of the conventional chemotherapeutic drugs in ABCB1-overexpressing leukemia cells in vitro
The chemical structural formula of ceritinib was presented in figure 1A . To investigate whether ceritinib could reverse MDR in vitro, we examined the cytotoxicity of ceritinib by MTT assay. The IC 50 values were 1.91 ± 0.4 μM and 1.15 ± 0.04 μM for K562/adr cells and K562 cells, respectively. More than 85% of both K562/adr cells and K562 cells survived at the concentration of 0.5 μM ceritinib (Fig. 1B) . Therefore, 0.5 μM of ceritinib was chosen as a maximum concentration used for combination treatment with ABCB1 substrate anti-cancer drug. The IC 50 values of the anti-cancer drugs in sensitive and resistant cells in the absence or presence of ceritinib were shown in Table 1 . Ceritinib was showed a concentrationdependent decrease in the IC 50 values of Dox and paclitaxel (both are ABCB1 substrates) in K562/adr cells, but ceritinib did not alter the cytotoxicity of cisplatin which is not an ABCB1 substrate. But only a slight enhancements of substrate agent Dox and paclitaxel and non-substrate agent cisplatin were observed in their parental sensitive K562 cells in the presence of ceritinib, even at the maximum reversal concentration of 0.5μM. In addition, ceritinib showed no significant reversal MDR effect on ABCC1-overexpressing HL60/adr cells. These results suggest that ceritinib enhances the sensitivity of ABCB1-overexpressing MDR leukemia cells to the conventional substrate chemotherapeutic drugs, but ceritinib has negligible effects on their parental sensitive cells.
Ceritinib enhanced the efficacy of Dox in ABCB1-overexpressing MDR leukemia cell xenograft model in vivo
An ABCB1-overexpressing MDR K562/adr cell xenograft model was established in nude mice to evaluate whether ceritinib could reverse the resistance to Dox in vivo. there was no significant difference in tumor size among animals treated with saline, ceritinib or Dox group. However, there was a significant inhibition of tumor growth in the group treated with a combination of ceritinib and Dox, compared with other single drug groups or saline control group (P < 0.05; Fig. 2A and Fig. 2B ). The mean weights of tumors excised from mice were 2.32 ± 0.26, 2.21 ± 0.31, 2.21 ± 0.57, and 0.88 ± 0.32 (g) for saline, Dox, ceritinib, and combination group, respectively. Furthermore, we did not observe the death of mice or apparent body weight loss in the combination treatment group at the treated doses (Fig. 2C) , suggesting that the combination regimen did not increase toxicity.
Ceritinib enhanced the accumulation of Dox and Rho123 in ABCB1-overexpressing MDR leukemia cells
The results described above revealed that ceritinib could enhance the sensitivity of ABCB1-overexpressing MDR leukemia cells to the conventional chemotherapeutic drugs was monitored and the results were showed in Fig. 4 . As expected, due to the ABCB1 overexpression in K562/ adr cells, Dox retention dropped remarkably from 100% (0 h efflux) to about 39.11% (2 h efflux), while ceritinib (0.5 μM) was found to significantly increase Dox retention in K562/adr cells to 63.02% (p < 0.05) of the level attained at the 2 h time point. Interestingly, we did not find any significant difference in sensitive parental K562 cells with or without ceritinib (0.5 μM). These results showed that ceritinib inhibited drug efflux function of ABCB1 in K562/adr cells, but ceritinib did not influence drug efflux in their parental sensitive K562 cells.
Ceritinib did not alter the expression level of ABCB1 in K562/adr cells
ABC transporter-mediated MDR may be circumvented by downregulating the expression of the transporters or inhibiting their transport function. Therefore, we determined the effect of ceritinib on the mRNA and protein expression levels of ABCB1 using RT-PCR and Western blot analysis, respectively. Our results, which were observed in K562/adr cells treated with 0.125, 0.25, or 0.5 μM ceritinib for 48 h or 0.5 μM ceritinib in different time of 72 h, showed no significant difference in ABCB1 expression at the mRNA or protein level (Fig. 5) . Therefore, it is likely that ceritinib reverses MDR by inhibiting the transport function of ABCB1 rather than downregulating the expression of ABCB1 transporter. 
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Ceritinib had no effect on the blockage of AKT and ERK1/2 phosphorylation in K562/adr cells at its MDR reversing concentrations
Previous studies have shown that activation of the AKT and ERK1/2 pathways resulted in the resistance to anti-cancer drugs in tumor cells [31, 32] . To determine whether the reversal MDR by ceritinib linked to the blockage of phosphorylation status of AKT and ERK1/2 in K562/adr cells and their parental cells, we examined the total and phosphorylation levels of AKT and ERK1/2 after concentration and time-dependently treating the cells with ceritinib. As shown in Fig. 6 , there was no significant alteration in the total and phosphorylated levels of AKT or ERK1/2 in the presence of ceritinib at the concentration of reversal MDR. These results suggest that the enhancement effect of ceritinib on ABCB1-overexpressing cells is independent of the inhibition of the total and phosphorylated AKT and ERK1/2 levels.
Ceritinib reversed MDR in ex vivo
To explore whether ceritinib could reverse ABCB1-mediated MDR in ex vivo, bone marrow samples were collected from drug-resistant leukemia patients [33] . We examined 10 leukemia patient's bone marrow samples in total. Among them, one patient was detected having a significantly higher ABCB1 expression (the ratio of ABCB1 expression is 44.1%) than the other patients (the ratio of ABCB1 expression is below 1%). We then examined the effect of ceritinib on the 
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Cellular Physiology and Biochemistry intracellular accumulation of Dox in leukemic blast cells from two patients (one was more than 44% ABCB1 expression; the other was less than 1% ABCB1 expression as negative control) using flow cytometric analysis. Our results showed that ceritinib increased the intracellular accumulation of Dox in leukemic blast cells with ABCB1-overexpressing patient (Fig. 7B1, C1 ), but not in leukemic blast cells with negative ABCB1 expressing patient (Fig.  7B2, C2 ). In addition, we used the MTT assay to assess the sensitizing effect of ceritinib in the primary leukemia cells. As shown in Fig. 7D1 , ceritinib at 0.5 μM significantly increased the sensitivity of the ABCB1 overexpressing primary leukemia cells to Dox, while we did not observe the same effect in the primary leukemia cells with the negative ABCB1 expression (Fig. 7D2) (p<0.05) . These results reveal that ceritinib enhances the efficacy of the substrate conventional chemotherapeutic drug in ABCB1-overexpressing primary leukemia cells, and it may be useful in combination regimen to combat ABCB1-mediated MDR in clinic. The schematic model illustrating the reversal of MDR by ceritinib is shown in Fig. 8 .
Discussion
A chemotherapeutic drug has to reach its effective concentration around or inside of tumor cells, before it can inhibit or kill the tumor cells. The intracellular drug concentration is dependent on various parameters including absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) [34] . Among them, one of the major groups of transporters involved in ADME-Tox is the ABC superfamily, especially the ABCB1 protein. The ABCB1 is expressed at a low or very low level in normal hematopoietic cells, while having a high expression level in some MDR leukemia cells. Many clinical studies have shown that ABCB1 expression level has an inverse relationship with treatment outcome in leukemia [11, 35, 36] . With the [36] [37] [38] . However, the toxicity of these drugs restricts their clinic use. More efficient and low toxicity reversal drugs still need to be sought. Ceritinib (LDK378/Zykadia) is a clinically approved second generation TKI specifically targeting the ALK, which has been found to be more potent than the first generation ALK inhibitor crizotinib in the therapy of non-small cell lung cancer (NSCLC) [36, 37, 39] . Our previous study showed that ceritinib had potent reversing activity in ABCB1-expressing MDR solid tumor cells in vitro and in vivo, through competing with substrates to interact with the substrate-binding sites of ABCB1, thereby inhibiting the efflux activity of the ABCB1 transporter [39] . It has been reported that the expression and function of ABC transporters differ in different human races, tumor types, and cell or tissue types [40] . Therefore, we hypothesized that leukemia cells and solid tumor cells were also different in terms of ABCB1-mediated drug resistance. To this end, we used the leukemia cell lines K562 and K562/adr to test whether ceritinib, like in solid tumor [39] , could also enhance the efficacy of conventional chemotherapeutic drugs in human ABCB1-overexpressing MDR leukemia. In fact, our data support that ceritinib can inhibit the efflux of ABCB1-mediated the conventional chemotherapeutic drugs to enhance the accumulation of these drugs in MDR leukemia cells, and to restore the sensitivity of ABCB1-overexpressing MDR cells to these conventional chemotherapeutic drugs, while having weak effect on their parental cells. Additionally, although ceritinib has been shown excellent antiproliferation activity in different ALK-positive cancer cells by inhibiting ALK phosphorylation and subsequent downstream survival signaling of ALK, such as ERK, p-ERK, AKT and p-AKT [41] , some studies also have shown that activation of ERK or PI3K/AKT pathway is attributable to the resistance to conventional chemotherapeutic drugs in various cancer cells [42, 43] . In our study, we found that ceritinib could reverse ABCB1-mediated MDR and enhance the efficacy of conventional chemotherapeutic drugs at more than 85% cell survival concentration. These effects were not due to ALK inhibition by ceritinib, because we did not find that ceritinib blocked the phosphorylation of AKT and ERK1/2 both in K562 and K562/adr cells. It suggests that 
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Cellular Physiology and Biochemistry ceritinib-induced enhancement of the cytotoxicity of chemotherapeutic drugs in K562/adr cells is not dependent on its antagonism of the phosphorylation of AKT or ERK1/2. Besides, in our study, ceritinib had also been testified to have a reversal MDR action in nude mice model. Even more importantly, ceritinib as a reversal agent was also verified to play a role in the ABCB1-overexpressing primary leukemia cells due to increasing the accumulation of Dox in a concentration-dependent manner and enhancing the cytotoxicity of Dox. All these results provide us a possibility that combining conventional chemotherapeutic drugs with ceritinib can increase the efficacy of chemotherapy and delay disease progression in the future leukemia therapy.
Conclusion
Taken together, our study portends a possibility that the detection of ABCB1 expression in all leukemia patients, especially in refractory or relapsed leukemia patients, is needed in the future clinic practice, and according to ABCB1 expression level, a suitable dose of ceritinib that inhibits the function of ABCB1 can be chosen to sensitize MDR cells to concurrent chemotherapy drugs used in clinic.
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